-
1Academic Journal
المؤلفون: O S Levin, D Y Olyunin, L V Golubeva
المصدر: Научно-практическая ревматология, Vol 42, Iss 4, Pp 80-84 (2004)
مصطلحات موضوعية: alflutop, chronic vertebrogenous lumbar ischialgia, Diseases of the musculoskeletal system, RC925-935
وصف الملف: electronic resource
-
2
المؤلفون: A. Gordeev, E. Matianova, Y. Olyunin, E. Galushko
المصدر: Annals of the Rheumatic Diseases. 81:1239.1-1239
مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology
-
3
المؤلفون: E. Matianova, A. Gordeev, Y. Olyunin, E. Galushko
المصدر: Annals of the Rheumatic Diseases. 81:1218.2-1218
مصطلحات موضوعية: Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology
-
4Academic Journal
المؤلفون: Y Olyunin A, Юрий Олюнин Алексанрович
المصدر: Rheumatology Science and Practice; Vol 46, No 5 (2008); 39-46 ; Научно-практическая ревматология; Vol 46, No 5 (2008); 39-46 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2008-5
وصف الملف: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/551/259; Pan C.Q., Zhang J.X. Natural history and clinical consequences of Hepatitis В Virus Infection. Int. J. Med. Sci., 2005, 2(1), 36-40. Chen S.L., Morgan T.R. The natural history of hepatitis С virus (HCV) infection. Int. J. Med. Sci., 2006, 3(2), 47-52. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis С virus infection in the United States. 1988 through 1994. N. Engl. J. Med., 1999, 19, 341(8), 556-562 Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol., 2005.34, suppl 1, Sl-3. Lauer G.M., Walker B.D. Hepatitis С virus infection. N. Engl. J. Med., 2001, 5, 345(1), 41-52. Zhang J., Zou S., Giulivi A. Epidemiology of hepatitis В in Canada. Can. J. Infect. Dis., 2001,12(6), 345350. Ganem D., Prince A.M. Hepatitis В virus infection- natural history and clinical consequences. N. Engl. J. Med., 2004, 350(11), 1118-1129. Galossi A., Guarisco R., Beilis L., Puoti C. Extrahepatic manifestations of chronic HCV infection. J. Gastrointestin. Liver Dis., 2007, 16(1), 65-73. Sterling R.K., Bralow S. Extrahepatic manifestations of hepatitis С virus. Curr. Gastiventerol. Rep., 2006, 8(1), 53-59. Zignego A.L., Ferri C., Giannini C. et al. Hepatitis С virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma: evidence for a pathogenetic role. Arch Virol., 1997, 142(3), 545-555. Sene D., Saadoun D., Lima! N. et at. Update in Hepatitis С virus associated extrahepatic manifestations. Rev. Med. Interne., 2007, 28(6), 388-393. Sansonno D., Comacchiulo V, lacobelli A.R. et at. Localization of hepatitis С virus antigens in liver and skin tissues of chronic hepatitis С virus-infected patients with mixed cryoglobulinemia. Hepatology 1995, 21(2), 305-312 Daghestani L., Pomeroy C. Renal manifestations of hepatitis С infection. Am. J. Med., 1999,106(3), 347354 Johnson R.J., Gretch D.R., Yamabe H. et al. Membranoproliferative glomerulonephritis associated with hepatitis С virus infection. N. Engl. J. Med., 1993, 328(7), 465-470. Ferri C., La Civita L., Cirafisi C. et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J. Rheumatol., 1992, 19(6), 889-895. Tembl J.I., Ferrer J. М., Sevilla М. T. el al. Neurologic complications associated with hepatitis С virus infection. Neurology, 1999, 53(4), 861-864. Dammacco F., Sansonno D., Piccoli C. et al. The lymphoid system in hepatitis С vims infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin. Liver Dis., 2000, 20(2), 143-157. Sata М., Nagao Y. Symposium on clinical aspects in hepatitis virus infection. 6. Hepatitis virus and extrahepatic manifestions—skin, mucosa, muscle, and hematopoietic organs. Intern. Med., 2001, 40(2), 185189. Gumber S.C., Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann. Intern. Med., 1995, 123(8),615-620. Loustaud-Ratti V, Lunel F. Extrahepatic manifestations of hepatitis С virus infection Rev. Prat., 2000, 50(10), 1089-1093. Ramos-Casals М., Trejo 0., Garcia-Carrasco М., Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis С virus infection. Rheumatology (Oxford), 2003, 42(7), 818-828. Strassburg C.P., Obermayer-Straub P., Manns M.P. Autoimmunity in hepatitis С and D virus infection. J. Viral. Hepat., 1996, 3(2), 49-59 Manns M.P, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatol- ogy. J. Viral. Hepat., 1997, 4suppl 2, 42-47. Haddad J., Deny P., Munz-Gotheil C. et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis С virus liver disease. Lancet, 1992, 339(8789), 321-323. Ramos-Casals М., De Vita S., Tzioufas A.G. Hepatitis С virus, Sjogren’s syndrome and В-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun. Rev., 2005, 4(1), 8-15 Giordano N., Amendola A., Papakostas P. et al. Immune and autoimmune disorders in HCV chronic liver disease: personal experience and commentary on literature. New Microbiol, 2005, 28(4), 311-317. Banks S. E., Riley T.R. 3rd, NaidesS.J. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis С and nonalcoholic fatty liver disease. Dig. Dis. Sci., 2007, 52(5), 1177-1182 Rosner I., Rozenbaum М., Toubi E. et al. The case for hepatitis С arthritis. Semin. Arthr. Rheum., 2004, 33(6), 375-387 Palazzi C., Olivieri I., Cacciatore P., etal. Management of hepatitis С virus-related arthritis. Expert Opin. Pharmacother., 2005, 6(1), 27-34 Zuckerman E., Yeshurun D. Rosner I. Management of hepatitis С virus-related arthritis. BioDrugs, 2001, 15(9), 573-584. Fadda P., La Civita L., Zignego A.L., Ferri C. Hepatitis С virus infection and arthritis. A clinico- serological investigation of arthritis in patients with or without cryoglobulinemic syndrome Reumatismo, 2002, 54(4), 316-323 Zuckerman E., Keren D., Rozenbaum M. et al. Hepatitis С virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin. Exp. Rheumatol., 2000 18(5), 579-584. Lienesch D., Morris R., Metzger A. et at. Absence of cyclic citrullinated peptide antibody in nonar- thritic patients with chronic hepatitis С infection. J. Rheumatol., 2005, 32(3), 489-493. Riedemann J.P., Munoz S., Kavanaugh A. The use of second generation anti-ССР antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review. Clin. Exp. Rheumatol., 2005, 23(5suppl39), S69-76 Bas S., Genevay S., Meyer O., Gabay C. Anti- cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford), 2003, 42(5),677-680 Meyer O., Labarre C., Dougados M. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann. Rheum. Dis., 2003, 62(2), 120-126 Wener M.H., Hutchinson K, Morishima C., Gretch D. R. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis С virus infection and cryoglobulinemia. Arthr. Rheum., 2004, 50(7), 2305-2308 Sene D., Ghillani-Dalbin P., Lima! N. et al. Anti- cyclic citrullinated peptide antibodies in hepatitis С virus associated rheumatological manifestations and Sjogren’s syndrome. Ann. Rheum. Dis., 2006, 65(3), 394-397. ' Bombardieri М., Alessandri C., Labbadia G., et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis С infection-associated polyarticular involvement. Arthr. Res. Ther., 2004, 6(2), R137-141. Riccio A., Postiglione L., La Dogana P. et al. Anti- cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J. Biol. Regul. Homeost. Agents, 2008, 22(1), 57-61. Nissen M.J., Fontanges E., Allam Y. et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford), 2005, 44(8), 1016-1020. Weigand K., Stremmel W., Encke J. Treatment of hepatitis С virus infection. World J. Gastroenterol 2007, 13(13), 1897-1905 Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358(9286), 958-965. Tarantino G., Riccio A., Spand A. et al. HCV infection and chronic arthritis: Does viral replication matter? Hepatol. Res., 2006, 35(4), 238-241. Marotte H., Fontanges E., Bailly F. et al. Etanercept treatment for three months is safe in patients with rheu- matological manifestations associated with hepatitis С virus. Rheumatology (Oxford), 2007, 46(1), 97-99. Olesinska М., Chwalinska-Sadowska H. Rheumatic syndromes during the course of HCV infection. Pol. Merkur. Lekarski, 2002, 12(68),119-121. Chuang E., Del Vecchio A., Smolinski S. et al. Biomedicines to reduce inflammation but not viral load in chronic HCV—what’s the sense ? Trends Biotechnol., 2004, 22(10), 517-523. Larrea E., Garcia N., Qian C. et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology, 1996, 23(2), 210-217 Zein N.N., Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis С virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol, 2005, 42(3), 315-322 Roccatello D., Baldovino S., Rossi D. et al. Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia. Clin. Rev. Allergy Immunol., 2008, 34(1), 111-117 Mason A. Role of viral replication in extraliepatic syndromes related to hepatitis В virus infection. Minerva Gastroenterol Dietol. 2006, 52(1), 53-66 Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin. Liver Dis., 2004, 8(2), 403-418. Gocke D.J. Extrahepatic manifestations of viral hepatitis. Am. J. Med. Sci., 1975, 270(1), 49-52 Toivanen A., Toivanen P. Which viruses should we look for in a recent onset polyarthritis. Acta Reumatol. Port., 2006, 31(1), 39-47. Chi Z.C., Ma S.Z. Rheumatologic manifestations of hepatic diseases. Hepatobiliaiy Pancreat. Dis. Int., 2003, 2(1), 32-37 Lee S. I., Yoo W.H., Yun H.J. et al. Absence of antibody to cyclic citrullinated peptide in sera of non- arthritic patients with chronic hepatitis В virus infection. Clin. Rheumatol., 2007, 26(7), 1079-1082. Coffin C.S., Lee S.S. Chronic hepatitis B—who should be treated? Med. Gen. Med., 2006, 8(1), 75. Abraham S., Begum S., Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann. Rheum. Dis., 2004, 63(2), 123-129. Maillefert J.F., Muller G., Falgarone G. et al. Prevalence of hepatitis С virus infection in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 635-637 Barbosa V.S., Silva N.A., Martins R.M. Hepatitis С virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz. J. Med. Biol. Res., 2005, 38(5),801-805 Mok M.Y., Ng W.L., Yuen M.F. et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin. Exp. Rheumatol., 2000, 18(3), 363-368. Е.В.Шекшина, P.M.Балабанова Инфекция и ревматоидный артрит: некоторые аспекты диагностики и лечения. Инфекц. антимикроб, тер., 2003, 3, 3-8 Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr. Rheum., 2008, 59(6), 762-784. Kujawska A., Clements М., Wise С.М., Roberts W.N. Hepatitis С and methotrexate. Arthr. Rheum., 2003, 49(6), 843-845. Roux C.H., Brocq 0., Breuil V. et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent В or С chronic hepatitis. Rheumatology (Oxford) 2006, 45(10), 12941297. Peterson JR., Hsu F.C., Simkin P.A., Wener M.H. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis С infection. Ann. Rheum. Dis., 2003, 62(11), 1078-1082. Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis С infection. Arthr. Rheum., 2004, 51(5), 800804. Cansu DM., KaliJ'oglu Т., Korkmaz C. Short-term course of chronic hepatitis В and С under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J. Rheumatol., 2008, 35(3), 421-424. Балабанова P.M., Вратских E.В. Эффективность комплексной терапии ревматоидного артрита с сопутствующим хроническим вирусным гепатитом С. Научно-практич. ревматол., 2003, 3, 74-76 M/son L.E., Widman D., Dikman S.H., Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis С virus infection. Semin. Arthr. Rheum., 2002, 32(3), 163-173. Sood A., Mid ha V., Sood N. Rheumatoid arthritis probably induced by pegylated interfemn in a patient with chronic hepatitis C. Indian J. Gastroenterol., 2004, 23(1), 28-29. Passos de Souza E., Evangelista Segundo P. Т., Jose F. F. et al. Rheumatoid arthritis induced by alpha- interferon therapy. Clin. Rheumatol., 2001, 20(4),297- 299 Niewold T.B., Gibofsky A. Concomitant interferon- alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthr. Rheum., 2006, 54(7), 2335-2337. Thong B.Y., Koh E.T., Chng H.H., Chow W.C. Outcomes of chronic hepatitis В infection in Oriental patients with rheumatic diseases. Ann. Acad. Med. Singapore, 2007, 36(2), 100-105. Helbling В., Reichen J. Reactivation of hepatitis В following withdrawal of chloroquine. Schweiz. Med. Wochenschr., 1994, 124(18), 759-762. Tsai F.C., Hsieh S.C., Chen D.S. et al. Reactivation of hepatitis В virus in rheumatologic patients receiving immunosuppressive agents. Dig. Dis. Sci., 2006, 51(9), 1627-1632. I to S., Nakazono K, Murasawa A. etal. Development of fulminant hepatitis В (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthr. Rheum., 2001, 44(2), 339-342 Ostuni P. Botsios C., Punzi L. et al. Hepatitis В reactivation in a chronic hepatitis В surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis., 2003, 62(7), 686-687. Tsutsumi Y., Kanamori H., Mori A. etal. Reactivation of hepatitis В virus with rituximab. Expert Opin. Drug Saf, 2005, 4(3), 599-608. KatzL.H., Fraser A., Gafter-GviliA., etal. Lamivudine prevents reactivation of hepatitis В and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral. Hepat., 2008, 15(2), 89-102. Michel М., Duvoux C., Hezode C., Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis В virus treated for an adult onset still’s disease. J. Rheumatol., 2003, 30(7), 1624-1625 Hagiyama H., Kubota Т., Komano Y. etal. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis В virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin. Exp. Rheumatol., 2004, 22(3), 375-376. Gwak G. Y, Koh K.C., Kim H. Y. Fatal hepatic failure associated with hepatitis В virus reactivation in a hepatitis В surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin. Exp. Rheumatol., 2007, 25(6), 888-889 Maillefert J.F., Sibilia J., Toussirot E. et al. Rheumatic disorders developed after hepatitis В vaccination. Rheumatology’ (Oxford), 1999, 38(10), 978-983. Pope J.E., Stevens A., Howson W., Bell D.A. The development of rheumatoid arthritis after recombinant hepatitis В vaccination. J. Rheumatol., 1998, 25(9), 1687-1693 Sibilia J., Maillefert J.F. Vaccination and rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 575-576. Elkayam 0., Yaron М., Caspi D. Safety and efficacy of vaccination against hepatitis В in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2002, 61(7), 623625; https://rsp.mediar-press.net/rsp/article/view/551
-
5
المؤلفون: Y. Olyunin, D. Kusevich, Nasonov El
المصدر: Annals of the Rheumatic Diseases. 80:1139.1-1139
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Rheumatoid arthritis, Internal medicine, Immunology and Allergy, Medicine, Rituximab, In patient, business, medicine.drug
-
6
المؤلفون: D. Kusevich, Nasonov El, Y. Olyunin
المصدر: Annals of the Rheumatic Diseases. 80:1131.2-1131
مصطلحات موضوعية: medicine.medical_specialty, Exacerbation, business.industry, Immunology, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Rheumatology, Clinical trial, Quartile, Rheumatoid arthritis, Internal medicine, Mann–Whitney U test, Immunology and Allergy, Medicine, Rituximab, Adverse effect, business, medicine.drug
-
7POS1455-HPR RELATIONSHIP BETWEEN PSYCHOLOGICAL FACTORS AND MEASURES OF RHEUMATOID ARTHRITIS ACTIVITY
المؤلفون: V. Rybakova, Y. Olyunin, E. Likhacheva, Nasonov El
المصدر: Annals of the Rheumatic Diseases. 80:1011.2-1011
مصطلحات موضوعية: medicine.medical_specialty, Rheumatology, business.industry, Internal medicine, Rheumatoid arthritis, Immunology, medicine, Immunology and Allergy, business, medicine.disease, General Biochemistry, Genetics and Molecular Biology
-
8
المؤلفون: Y. Olyunin, V. Rybakova, Nasonov El, A. S. Avdeeva
المصدر: Annals of the Rheumatic Diseases. 80:1134.2-1134
مصطلحات موضوعية: medicine.medical_specialty, Rheumatology, business.industry, Internal medicine, Rheumatoid arthritis, Immunology, medicine, Immunology and Allergy, Long term results, medicine.disease, business, General Biochemistry, Genetics and Molecular Biology
-
9
المؤلفون: E. L. Luchikhina, M. Kanonirova, N. Demidova, D.E. Karateev, Y. Olyunin, A.A. Novikov, Aleksandrova En, G. Loukina, Nasonov El
المصدر: Annals of the Rheumatic Diseases. 74:976.3-976
مصطلحات موضوعية: Drug, medicine.medical_specialty, Combination therapy, business.industry, Inflammatory arthritis, media_common.quotation_subject, Immunology, Treat to target, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Surgery, Disease activity, Rheumatology, Rheumatoid arthritis, Internal medicine, medicine, Immunology and Allergy, Methotrexate, In patient, business, media_common, medicine.drug
-
10
المؤلفون: Y. Olyunin, Nasonov El, M. Kanonirova, Y. Mouraviev, E. L. Luchikhina, N. Demidova, Galina Lukina, G. Gridneva, D.E. Karateev
المصدر: Annals of the Rheumatic Diseases. 73:235.2-236
مصطلحات موضوعية: medicine.medical_specialty, Combination therapy, business.industry, Inflammatory arthritis, Immunology, Treat to target, medicine.disease, Response to treatment, General Biochemistry, Genetics and Molecular Biology, Surgery, Clinical Practice, Rheumatology, Rheumatoid arthritis, Internal medicine, medicine, Immunology and Allergy, Methotrexate, In patient, business, medicine.drug
-
11
المؤلفون: D.E. Karateev, E. L. Luchikhina, N. Demidova, Y. Muravyev, Nasonov El, Galina Lukina, E. Lopareva, Y. Olyunin, G. Gridneva
المصدر: Annals of the Rheumatic Diseases. 72:A893.2-A893
مصطلحات موضوعية: musculoskeletal diseases, medicine.medical_specialty, Combination therapy, business.industry, Inflammatory arthritis, Abatacept, Immunology, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Surgery, Rheumatology, Rheumatoid arthritis, Internal medicine, medicine, Adalimumab, Immunology and Allergy, Methotrexate, Rituximab, Certolizumab pegol, business, medicine.drug